ALK and neoplasm: In the open-label, phase 1/2 study (NCT01970865), LOR was found to have intracranial and extracranial responses in patients with advanced NSCLC harboring ALK rearrangement, who experienced tumor progression during prior ALK TKI therapy, including alectinib.7